Cargando…
1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy
Autores principales: | Michot, J-M., Dozio, V., Danlos, F-X., Vasse, M., Rohmere, J., Roumier, M., Pommeret, F., Kishazi, E., Marabelle, A., Escher, C., Kakalacheva-Beeler, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506334/ http://dx.doi.org/10.1016/j.annonc.2020.08.1758 |
Ejemplares similares
-
High levels of TNFα in patients with COVID-19 refractory to tocilizumab
por: Danlos, F.X., et al.
Publicado: (2021) -
Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
por: Judson, I., et al.
Publicado: (1998) -
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
por: Michot, J.-M., et al.
Publicado: (2020) -
1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014) -
P1694: THROMBOSIS RISK ASSESSMENT IN LYMPHOMA PATIENTS - PROSPECTIVE PILOT SUDY
por: Antic, D., et al.
Publicado: (2022)